Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer

Authors: Azza M. Kamel, Salwa Teama, Amal Fawzy, Mervat El Deftar

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Plasma DNA integrity index is increased in various malignancies including breast cancer, the most common cancer in women worldwide; early detection is crucial for successful treatment. Current screening methods fail to detect many cases of breast cancer at an early stage. In this study, we evaluated the level of plasma DNA integrity index in 260 females (95 with breast cancer, 95 with benign breast lesions, and 70 healthy controls) to verify its potential value in discriminating malignant from benign breast lesions. The criteria of the American Joint Committee on Cancer were used for staging of breast cancer patients. DNA integrity index was measured by real-time PCR. DNA integrity index was significantly higher in breast cancer than in benign breast patients and healthy subjects (P = <0.001). DNA integrity index is correlated with TNM stage. Given 100 % specificity, the highest sensitivity achieved in detecting cancer group was 85.3 % at 0.55 DNA integrity index cutoff. In conclusion, the plasma DNA integrity index may be a promising molecular diagnostic marker of malignancy in breast lesions.
Appendix
Available only for authorised users
Literature
1.
Abdulrahman Jnr GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. Review article. J Cancer Epidemiol. 2012;2012, 915610. doi:10.​1155/​2012/​915610.
2.
3.
Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, El-Khatib O. Breast cancer in Egypt: a review of disease presentation and detection strategies. East Mediterr Health J = La Revue de Santé de la Méditerranée. 2003;9:448–63.
4.
Mandel P, Metais P. Circulating nucleic acid. Acad Sci Paris. 1948;142:241–3.
5.
Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63:3966–8.PubMed
6.
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50.PubMed
7.
Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983;51:2116–20.CrossRefPubMed
8.
Anker P, Stroun M. Circulating DNA in plasma or serum. Medicina (B Aires). 2000;60(5 Pt 2):699–702.
9.
Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma/serum as biomarker of carcinogenesis. Practical aspects and biological significance. Mutat Res. 2007;635:105–17.CrossRefPubMed
10.
11.
12.
Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell free DNA in human blood plasma, length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17:89–97.CrossRefPubMed
13.
Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor related protein. Nature. 1986;319(22):6–30.
14.
Pupa SM, Ménard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene. 1983;8:2917–23.
15.
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer: biomarker and target of therapy. Oncologist. 2003;8:307–25.CrossRefPubMed
16.
Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18:65–73.CrossRefPubMed
17.
Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci. 2004;1022:76–80.CrossRefPubMed
18.
Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004;205:173–80.CrossRefPubMed
19.
Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res. 2005;11:1394–9.CrossRefPubMed
20.
Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119:1219–27.CrossRefPubMed
21.
Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67–71.PubMed
22.
Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86:774–9.CrossRefPubMed
23.
Jiajia Y, Guohao G, Shaoqing J. Recent advances in clinical applications of circulating cell-free DNA integrity. Lab Med. 2014;45:6–12.CrossRef
24.
Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem. 2003;49:1058–65.CrossRefPubMed
25.
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–65.PubMed
26.
Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996;2:1033–5.CrossRefPubMed
27.
Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2:1035–7.CrossRefPubMed
28.
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59:67–70.PubMed
29.
Maebo A. Plasma DNA level as a tumor marker in primary lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28:1085–91 (Abstract).PubMed
30.
Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24:4270–6.CrossRefPubMed
31.
Chang H-W, Lee SM, Goodman SN, Singer G, Cho S, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002;94:1697–703.CrossRefPubMed
32.
Agassi R, Czeiger D, Shaked G, Avriel A, Sheynin J, Lavrnkov K, et al. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am J Clin Pathol. 2015;143(1):18–24. doi:10.​1309/​AJCPI5YHG0OGFAHM​.CrossRefPubMed
33.
El-Shazly SF, Eid MA, El-Sourogy HA, Attia GF, Ezzat SA. Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virus-related hepatocellular carcinoma. Int J Biol Markers. 2010;25:79–86.PubMed
34.
35.
36.
Kamel AM, Teama S, Fawzy A, El Deftar M. Increased plasma DNA integrity index in breast cancer patients. AACC. 2011; Abstract 09.
37.
Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001;61:4675–8.PubMed
38.
Hanley R, Rieger-Christ KM, Canes D, Emara NR, Shuber AP, Boynton KA, et al. DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res. 2006;12:4569–74.CrossRefPubMed
39.
40.
41.
42.
Sriram KB, Relan V, Clarke BE, Duhig EE, Windsor MN, Matar KS, et al. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer. 2012;12:428. doi:10.​1186/​1471-2407-12-428.CrossRefPubMed
43.
44.
Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 2014;146:163–73. doi:10.​1007/​s10549-014-2946-2.CrossRefPubMed
45.
46.
47.
Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer. 2008;122:138–43.CrossRefPubMed
Metadata
Title
Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer
Authors
Azza M. Kamel
Salwa Teama
Amal Fawzy
Mervat El Deftar
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4624-3

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Original Article

MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma

Original Article

MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response

Original Article

The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma

Original Article

Immunomodulatory and cellular antioxidant activities of pure compounds from Teucrium ramosissimum Desf.

Review

DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Original Article

Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits